Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade

Shares of Bioventus Inc. (NASDAQ:BVS) gapped up before the market opened on Monday after Barrington Research upgraded the stock to a strong-buy rating. The stock had previously closed at $8.51, but opened at $9.03. Bioventus shares last traded at $8.60, with a volume of 102,601 shares.

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Bioventus presently has a consensus rating of “Buy”.

Bioventus Stock Down 5.3%

The company has a quick ratio of 1.14, a current ratio of 1.74 and a debt-to-equity ratio of 1.50. The business has a 50-day simple moving average of $7.73 and a two-hundred day simple moving average of $7.29. The stock has a market capitalization of $667.87 million, a P/E ratio of 67.26 and a beta of 0.80.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.